
國中小半導體科普教材教師研習計畫啟動
國立科學工藝博物館與台灣默克公司合作推動「國中小半導體科普教材」教師研習計畫,將半導體知識轉化為趣味課堂體驗,並融入生活科技與藝術,旨在提升學子科學素養,並落實智慧製造科技於教學中。

國立科學工藝博物館與台灣默克公司合作推動「國中小半導體科普教材」教師研習計畫,將半導體知識轉化為趣味課堂體驗,並融入生活科技與藝術,旨在提升學子科學素養,並落實智慧製造科技於教學中。

Jonas Vingegaard has achieved a cycling Grand Slam by winning the Giro d'Italia, joining an elite group of champions. The Dane overcame life-threatening injuries from a 2024 crash to secure his fourth Grand Tour victory.

Jonas Vingegaard secured his Giro d'Italia victory in Rome, becoming one of the few cyclists to win all three Grand Tours. He now prepares for a Tour de France duel with Tadej Pogacar.

Cơ thủ Việt Nam Nguyễn Quốc Hồng Thái đã ngược dòng đánh bại Eddy Merckx 50-46 ở tứ kết World Cup carom 3 băng tại TP.HCM, lần đầu tiên vào bán kết giải đấu danh giá này.

Filippo Ganna domina la cronometro Viareggio-Massa del Giro d'Italia 2026, vincendo la tappa e eguagliando Eddy Merckx con 7 vittorie in crono alla Corsa Rosa. La maglia rosa resta sulle spalle di Afonso Eulálio.

Verschiedene deutsche und europäische Unternehmen wie Sonova, Ryanair, Nagarro, Freenet, O2, MediaForEurope, Südzucker, Birkenstock, HHLA, Porsche SE, RTL Group, Merck, SMA Solar, Sixt und LEG legen ihre Quartalsberichte vor, die sowohl Wachstum als auch Herausforderungen wie steigende Kosten und wirtschaftliche Unsicherheiten zeigen.

Représenté dans la commune bruxelloise de Woluwe-Saint-Pierre, le visage de la légende du cyclisme belge a été arraché, selon un communiqué des autorités locales mercredi.

Il est possible de remporter le Tour de France pour une première participation mais personne n’y est encore parvenu à un âge aussi précoce que celui de Paul Seixas.

Merck reported first-quarter 2026 results exceeding Wall Street expectations with $16.29B revenue, driven by strong Keytruda sales of $8.03B (up 12%). The pharma giant narrowed its 2026 revenue guidance to $65.8B-$67B and raised adjusted earnings outlook to $5.04-$5.16 per share. The company posted a net loss of $4.24B due to a $3.62 per share charge from its Cidara Therapeutics acquisition, part of its strategy to offset upcoming generic competition for Keytruda in 2028 and diabetes drugs Januvia/Janumet later this year.